(San Francisco) -- Dr. Bradly Jacobs will present Mytrus’ direct to patient clinical trials application during the Health 2.0 conference in San Francisco next week. Dr. Jacobs will be part of a panel of new companies with emerging and innovative Internet technologies.
"Mytrus is a perfect fit for the Health 2.0 movement" said Dr. Jacobs, Senior Medical Director at Mytrus. "Our mission, to enable and empower patients to participate in studies most relevant to them, resonates with the family of Health 2.0 companies. Many of them have become our partners in efforts to recruit patients to these revolutionary new clinical trials."
Mytrus is also a lead sponsor of the Health 2.0 conference.
Founded in 2009, Mytrus is a privately held e-clinical technology company specializing in patient-centered electronic informed consent and data collection tools. After receiving the first FDA approvals for remote electronic consent and virtual data collection, Mytrus has gone on to develop new technologies for patients including ePRO and EDC tools usable from home and mobile devices, bio-sample consent tracking technology, site training and e-learning applications, and patient home dashboards for tracking clinical study progress and data. Mytrus also holds an exclusive patent for conducting virtual clinical trials in the US. Mytrus investors include BioClinica and inVentiv Health.